Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.050
-0.010 (-0.49%)
At close: Dec 5, 2025, 4:00 PM EST
2.040
-0.010 (-0.49%)
After-hours: Dec 5, 2025, 7:53 PM EST
Outlook Therapeutics Revenue
Outlook Therapeutics had revenue of $1.51M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $1.51M.
Revenue (ttm)
$1.51M
Revenue Growth
n/a
P/S Ratio
39.40
Revenue / Employee
$65,449
Employees
23
Market Cap
91.06M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OTLK News
- 12 days ago - Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 23 days ago - Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Provides Update on Type A Meeting with FDA - GlobeNewsWire
- 3 months ago - Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewsWire
- 3 months ago - Outlook Therapeutics Requests Type A Meeting with FDA - GlobeNewsWire
- 3 months ago - Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug - Invezz
- 3 months ago - FDA Rejects Outlook Therapeutics Eye Drug For Second Time - Benzinga